ForViva (LON:FVA – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Canaccord Genuity Group in a research report issued on Friday,Digital Look reports. They presently have a GBX 190 price objective on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 37.68% from the company’s current price.
Separately, Shore Capital Group reiterated a “hold” rating on shares of ForViva in a research note on Friday, April 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of GBX 190.
ForViva Trading Down 0.4%
Insider Buying and Selling
In other ForViva news, insider Tim Jones purchased 40,000 shares of the company’s stock in a transaction that occurred on Friday, July 17th. The shares were acquired at an average cost of GBX 138 per share, for a total transaction of £55,200. Insiders acquired 90,000 shares of company stock worth $12,380,000 in the last 90 days. Company insiders own 7.31% of the company’s stock.
ForViva Company Profile
ForViva plc (LON: FVA) is a United Kingdom–based property company that operates in the residential and specialist housing sectors. The group’s activities are focused on ownership, management and leasing of housing assets that serve social, affordable and supported living needs. Its portfolio is oriented toward providing long‑term rental accommodation and specialist premises that accommodate people requiring additional care or support.
Services associated with ForViva’s property portfolio typically include day‑to‑day asset management, tenancy management, property maintenance and refurbishment, and collaboration with public sector bodies and third‑party care providers to deliver supported housing solutions.
Further Reading
- Five stocks we like better than ForViva
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for ForViva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ForViva and related companies with MarketBeat.com's FREE daily email newsletter.
